PortfoliosLab logoPortfoliosLab logo

Documentation

Upgrade your plan

Future Health ETF (BMED) Sharpe Ratio: 1.64

ETF · Currency in USD · Last updated Aug 2, 2026

BMED is an actively managed ETF by BlackRock. BMED launched on Sep 29, 2020 and has a 0.85% expense ratio.

BMED's Sharpe Ratio of 1.64 indicates that for each unit of volatility, it generates 1.64 units of excess return above the risk-free rate. The ratio is calculated using historical daily returns over the past 12 months (as of Aug 2, 2026).

Sharpe uses total volatility (standard deviation) which includes both upside and downside price movements, making it useful for comparing risk-adjusted returns across different assets. For how to read this number and when it can mislead, see Sharpe Ratio Explained.

BMED Sharpe Ratio Rank

BMED Sharpe Ratio Rank: 71.972
Above Average

BMED ranks above 71.9% of all investments in our database based on Sharpe Ratio over the past 12 months, indicating above-average returns relative to volatility. Securities are ranked from 0 (worst) to 100 (best).

What moves the rank

  • Strong returns with low total volatility → Higher rank
  • High volatility (both upside and downside) → Lower rank
  • Consistent returns → Higher rank than volatile returns of same magnitude
  • Sharp drawdowns increase volatility → Lower rank

What you can do with this information

  • Above-average risk-adjusted returns with room for improvement
  • Compare against category peers to gauge relative positioning
  • Monitor for movement toward top tier or decline toward median
  • Consider pairing with top-tier holdings to improve portfolio efficiency

BMED Sharpe Ratio Market Positioning

The chart shows BMED's Sharpe Ratio relative to all ETFs on our platform, with color zones indicating percentile rankings. Higher ratios indicate better risk-adjusted returns.

  • Red zone (bottom 25%): 0.56 or lower
  • Yellow zone (middle 50%): 0.56 to 1.74
  • Green zone (top 25%): 1.74 or higher
  • Top 1%: 6.41+
  • Median: 1.25 — half of all investments score higher

How it compares to other similar ETFs

The table compares Future Health ETF's Sharpe Ratio with other ETFs in the Health & Biotech Equities category across multiple time periods, showing how BMED's risk-adjusted performance compares to similar funds.

Data shows 1-, 5-, and 10-year periods, plus each fund's all-time average, as of Aug 2, 2026.

SymbolName1Y Sharpe Ratio5Y Sharpe Ratio10Y Sharpe RatioAll Time Sharpe Ratio
BBCVirtus LifeSci Biotech Clinical Trials ETF3.55
LFSCF/m Emerald Life Sciences Innovation ETF3.25
IHEiShares U.S. Pharmaceuticals ETF3.23
FTXHFirst Trust Nasdaq Pharmaceuticals ETF3.12
PJPInvesco Dynamic Pharmaceuticals ETF3.10
SBIOALPS Medical Breakthroughs ETF3.05
XPHSPDR S&P Pharmaceuticals ETF2.95
XHSSPDR S&P Health Care Services ETF2.75
XBISPDR S&P Biotech ETF2.70
CANCTema Oncology ETF2.51
BMEDFuture Health ETF1.64
Benchmark

Compare this symbol against anything

Time Period

How much price history to include in the calculation

Historical Sharpe Ratio

The chart shows BMED's rolling Sharpe ratio over time compared to your chosen benchmark. Rising trends indicate improving returns relative to total volatility, while declining trends may signal deteriorating risk-adjusted performance or increased volatility. Use multiple timeframes to distinguish short-term fluctuations from long-term patterns.

Identify market cycles by observing when BMED consistently outperforms (line above benchmark), underperforms (below benchmark), or aligns with the benchmark.

Loading charts...

Sharpe Ratio Calculator

How does BMED fit in your portfolio?

Add your other holdings to see your portfolio's Sharpe Ratio and find out.

Analyze Your Portfolio